The Medicines Co. and Bristol-Myers' Recothrom collaboration becomes effective The Medicines Company (MDCO) announced that the global license and two-year collaboration for Recothrom, a recombinant thrombin approved by the FDA for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (BMY), has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.
News For MDCO;BMY From The Last 14 Days
Check below for free stories on MDCO;BMY the last two weeks.